Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating.

The mechanics of a PM deal are complex. Contracts are increasingly nuanced and bespoke, including caveats and clawbacks.

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs. Net profit for the fourth ...

Obesity drug maker Novo Nordisk has forecast slower growth this ... Jorgensen told journalists on a call. Lukas Leu, fund manager at healthcare-focused Bellevue Asset Management in Switzerland ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter ... through license agreements or subscriptions. Our investment management business generates asset-based fees, which are ...

Obesity drug maker Novo Nordisk NVO-N forecast slower growth this ... to report its earnings on Thursday. Lukas Leu, fund manager at healthcare-focused Bellevue Asset Management in Switzerland ...